Erratum

CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells (Leukemia (2009) vol. 23 (1329-1336) 10.1038/leukemia.2009.77)

A. Takeshita, N. Yamakage, K. Shinjo, T. Ono, I. Hirano, S. Nakamura, K. Shigeno, T. Tobita, M. Maekawa, H. Kiyoi, T. Naoe, K. Ohnishi, Yoshikazu Sugimoto, R. Ohno

Research output: Contribution to journalArticle

1 Citation (Scopus)
Original languageEnglish
Pages (from-to)1372
Number of pages1
JournalLeukemia
Volume23
Issue number7
DOIs
Publication statusPublished - 2009
Externally publishedYes

Fingerprint

B-Cell Leukemia
Inotuzumab Ozogamicin

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Erratum : CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells (Leukemia (2009) vol. 23 (1329-1336) 10.1038/leukemia.2009.77). / Takeshita, A.; Yamakage, N.; Shinjo, K.; Ono, T.; Hirano, I.; Nakamura, S.; Shigeno, K.; Tobita, T.; Maekawa, M.; Kiyoi, H.; Naoe, T.; Ohnishi, K.; Sugimoto, Yoshikazu; Ohno, R.

In: Leukemia, Vol. 23, No. 7, 2009, p. 1372.

Research output: Contribution to journalArticle

Takeshita, A, Yamakage, N, Shinjo, K, Ono, T, Hirano, I, Nakamura, S, Shigeno, K, Tobita, T, Maekawa, M, Kiyoi, H, Naoe, T, Ohnishi, K, Sugimoto, Y & Ohno, R 2009, 'Erratum: CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells (Leukemia (2009) vol. 23 (1329-1336) 10.1038/leukemia.2009.77)', Leukemia, vol. 23, no. 7, pp. 1372. https://doi.org/10.1038/leu.2009.115
Takeshita, A. ; Yamakage, N. ; Shinjo, K. ; Ono, T. ; Hirano, I. ; Nakamura, S. ; Shigeno, K. ; Tobita, T. ; Maekawa, M. ; Kiyoi, H. ; Naoe, T. ; Ohnishi, K. ; Sugimoto, Yoshikazu ; Ohno, R. / Erratum : CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells (Leukemia (2009) vol. 23 (1329-1336) 10.1038/leukemia.2009.77). In: Leukemia. 2009 ; Vol. 23, No. 7. pp. 1372.
@article{1f2d792daf2847d6ba4549424077dc4f,
title = "Erratum: CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells (Leukemia (2009) vol. 23 (1329-1336) 10.1038/leukemia.2009.77)",
author = "A. Takeshita and N. Yamakage and K. Shinjo and T. Ono and I. Hirano and S. Nakamura and K. Shigeno and T. Tobita and M. Maekawa and H. Kiyoi and T. Naoe and K. Ohnishi and Yoshikazu Sugimoto and R. Ohno",
year = "2009",
doi = "10.1038/leu.2009.115",
language = "English",
volume = "23",
pages = "1372",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Erratum

T2 - CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells (Leukemia (2009) vol. 23 (1329-1336) 10.1038/leukemia.2009.77)

AU - Takeshita, A.

AU - Yamakage, N.

AU - Shinjo, K.

AU - Ono, T.

AU - Hirano, I.

AU - Nakamura, S.

AU - Shigeno, K.

AU - Tobita, T.

AU - Maekawa, M.

AU - Kiyoi, H.

AU - Naoe, T.

AU - Ohnishi, K.

AU - Sugimoto, Yoshikazu

AU - Ohno, R.

PY - 2009

Y1 - 2009

UR - http://www.scopus.com/inward/record.url?scp=67650868986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650868986&partnerID=8YFLogxK

U2 - 10.1038/leu.2009.115

DO - 10.1038/leu.2009.115

M3 - Article

VL - 23

SP - 1372

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 7

ER -